Posted in

Recent News

COMPPARE Enrolls 1,000th Photon Patient

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC,…

September is Prostate Cancer Awareness Month

If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist and the…

COMPPARE Enrolls 1,500th Proton Patient, Reaches Cohort Goal

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

COMPPARE Achieves 75% Enrollment Milestone

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

From Principles to Practice: Building Partnerships for Trust and Equity in Health Research with COMPPARE

On November 17, Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, participated in a special panel discussion entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” during the 7th annual meeting of the Patient-Centered Outcomes Research Institute (PCORI). “This year’s…

COMPPARE Reaches Its Pragmatic Proton Patient Enrollment Goal

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…

COMPPARE Invited To Participate in Annual PCORI Meeting

Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, have been invited to participate in the seventh annual meeting of the Patient-Centered Outcomes Research Institute (PCORI), to be held virtually in November. Dr. Mendenhall and Mr. Griggs will contribute as panelists in a session focused on…

COMPPARE Study Highlighted in Cancer Connections Presentation

On February 17, 2021, Cancer Connections, a UF Monthly Educational & Networking Meeting, presented “COMPPARE Clinical Trial: Protons vs Photons to Treat Prostate Cancer.” Dr. Nancy Mendenhall, M.D., FACR, FASTRO, COMPPARE Principal Investigator, provided an overview of the UF-led national ongoing prostate cancer clinical trial, highlighting the differences between between…

Contact the COMPPARE Team